Pharmaceutical Executive-06-01-2019

Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market.

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.

Changing customer preferences and a growing need for specialized knowledge are challenging the traditional scope of the medical affairs function. Learn about six ways pharma MA departments can drive more collaborative relationships with caregivers.

Exploring the critical go-to strategies for biopharma C-suite executives in navigating organizational disruption and the impact of global change and volatility on their employees and business.

Our latest rankings and report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.

With a new Commission looming, here’s who’s vying for the top spot in shaping EU strategy, including key questions in pharma.

With little momentum in developing new new antibiotics to fight antimicrobial resistance, the time is now to emphasize "push" and "pull" incentives and demonstrate how innovation in this area will lead to patient benefit and economic reward.

Cell and gene therapies in crosshairs of pricing focus, prompting stepped-up proposals on ways to finance these products.

Click the title above to open the Pharmaceutical Executive June 2019 issue in an interactive PDF format.

Repurposing existing technology to alleviate traditional ‘pain points’ in ensuring clinical investigator payments transparency

Key staffing strategies for emerging biopharma entrepreneurs in attracting the talent to bring their visions and ideas to life.

After several years of losing pace to many of its European peers when it comes to pharma production and R&D, France’s life sciences market, sparked by a renewed spirit of reform, is now squarely back on the radar of the international investor community.